首页 | 本学科首页   官方微博 | 高级检索  
检索        


The extent of HLA‐DR expression on HLA‐DR+ Tregs allows the identification of patients with clinically relevant borderline rejection
Authors:Matthias Schaier  Nicole Seissler  Luis Eduardo Becker  Sebastian Markus Schaefer  Edgar Schmitt  Stefan Meuer  Friederike Hug  Claudia Sommerer  Rüdiger Waldherr  Martin Zeier  Andrea Steinborn
Institution:1. Department of Nephrology, University of Heidelberg, , Germany;2. Department of Pathology, University of Heidelberg, , Germany;3. Institute of Immunology, University of Mainz, , Germany;4. Institute of Immunology, University of Heidelberg, , Germany;5. Department of Obstetrics and Gynecology, University of Heidelberg, , Germany
Abstract:Regulatory T cells (Tregs) were shown to be involved into the pathogenesis of acute rejection after transplantation. The suppressive activity of the total regulatory T cell pool depends on its percentage of highly suppressive HLA‐DR+‐Treg cells. Therefore, both the suppressive activity of the total Treg pool and the extent of HLA‐DR expression of HLA‐DR+‐Tregs (MFI HLA‐DR) were estimated in non transplanted volunteers, patients with end‐stage renal failure (ESRF), healthy renal transplant patients with suspicion on rejection, due to sole histological Bord‐R or sole acute renal failure (ARF), and patients with clinically relevant borderline rejection (Bord‐R and ARF). Compared to patients with only Bord‐R or only ARF, the suppressive activity of the total Treg cell pool was exclusively reduced in patients with clinically relevant Bord‐R. In parallel, the HLA‐DR MFI of the DR+‐Treg subset was significantly decreased in these patients, due to a significantly lower proportion of DRhigh+‐Tregs, which were shown to have the highest suppressive capacity within the total Treg pool. Our findings clearly demonstrate that the determination of the HLA‐DR MFI of the HLA‐DR+‐Treg subset allows a highly sensitive, specific and non‐invasive discrimination between patients with clinically relevant Bord‐R (Bord and ARF) and patients with subclinical rejection or other causes of transplant failure.
Keywords:borderline rejection  non‐invasive marker  renal transplantation  Tregs
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号